Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIG<i>MS</i> Study.

BMJ Neurol Open · 2022 · PMC8883212 · PMID 35308898

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The Total Scale and Physical Health Summary Scores were greater for the fingolimod group (p≤0.05) in the parent-reported questionnaires, whereas the Psychosocial Health Summary Score (including Emotional, Social and School Functioning) favoured fingolimod but did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.